This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon: Biotech Stock Mailbag

Jack S. brings up a strange case of non-disclosure at GTx (GTXI) concerning the company's experimental hormone drug Ostarine, which is (was?) partnered with Merck (MRK - Get Report). " Merck terminated the development of Ostarine, as reported in its 10-K. My calls to GTx have not been returned. This would seem to be a huge blow to GTx and I'm shocked they haven't made a press release on this as of yet."

On page 128 of its annual report filed March 1 with the SEC, Merck (newly merged with the old Schering-Plough) says this about Ostarine, referred to here as MK-2866:

"Also in 2007, Old Merck and GTx, Inc. entered into an agreement providing for a research and development and global strategic collaboration for selective androgen receptor modulators ("SARMs"), a new class of drugs with the potential to treat age-related muscle loss (sarcopenia) as well as other musculoskeletal conditions. Merck has discontinued internal development of MK-2866 (which is a SARM) under this agreement, and is currently discussing next steps with GTx."

In response, GTx spokesman McDavid Stillwell told me, "We have no comment yet, but we will have one. I'm not sure when, but fairly soon."

Ostarine (MK-2866) is a very important drug in GTx's pipeline and the collaboration with Merck helped validate the drug and added to GTX's market valuation. GTx's stock price has taken a hit this week as word of Merck's exit leaked out.

GTx announces fourth-quarter financial results on March 15, so perhaps the company will say something then about the fate of Ostarine.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
GPRO $49.98 0.00%
GTXI $0.77 0.00%
MDVN $125.41 0.00%
MRK $59.86 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs